1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
ALEXION PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, PAR VALUE $.0001 PER SHARE
-------------------------------------------------------------------------------
(Title of Class of Securities)
015351109
--------------------------
(CUSIP Number)
-------------------------------------------------------------------------------
(Date of Event Which Requires Filing This Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed " for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 6 pages
2
CUSIP No. 015351109
-------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BB BIOTECH AG
-------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See
Instructions)
(a) [X]
(b) []
-------------------------------------------------------------------------------
3. SEC Use Only
-------------------------------------------------------------------------------
4. Citizenship or Place of Organization
SWITZERLAND
-------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Beneficially -0-
Owned by Each
Reporting -------------------------------------------------------
Person With:
6. Shared Voting Power
874,113
-------------------------------------------------------
7. Sole Dispositive Power
-0-
-------------------------------------------------------
8. Shared Dispositive Power
874,113
-------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
874,113
10. Check if the Aggregate Amount in Row (11) Excludes Certain
shares
11. Percent of Class Represented by amount in Row (11)
4.9%
-------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions) HC, CO
-------------------------------------------------------------------------------
Page 2 of 6 pages
3
CUSIP No. 015351109
-------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
BIOTECH TARGET S.A.
-------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(a) [X]
(b) []
-------------------------------------------------------------------------------
3. SEC Use Only
-------------------------------------------------------------------------------
4. Citizenship or Place of Organization
PANAMA
-------------------------------------------------------------------------------
Number of 5. Sole Voting Power
Shares Beneficially -0-
Owned by Each
Reporting -------------------------------------------------------
Person With:
6. Shared Voting Power
874,113
-------------------------------------------------------
7. Sole Dispositive Power
-0-
-------------------------------------------------------
8. Shared Dispositive Power
874,113
-------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
874,113
10. Check if the Aggregate Amount in Row (11) Excludes Certain
shares
11. Percent of Class Represented by amount in Row (11)
4.9%
-------------------------------------------------------------------------------
12. Type of Reporting Person
CO
----------------------------------------------------------------------------
Page 3 of 6 pages
4
CUSIP No. 015351109
-------------------------------------------------------------------------------
ITEM 2.
(a) Name of Person Filing
BB Biotech AG ("BB Biotech")
Biotech Target S.A. ("Biotech Target")
(b) Address of Principal Business Office or, if none, Residence
BB Biotech Biotech Target
Vordergasse 3 Swiss Bank Tower
8200 Schaffhausen Panama 1
CH/Switzerland Republic of Panama
(c) Citizenship
See Item No. 4 of cover pages.
(d) Title of Class of Securities
Common Stock, Par Value $.0001 Per Share
(e) CUSIP Number
015351109
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
874,113
(b) Percent of class:
4.9%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
-0-
(ii) Shared power to vote or to direct the vote
874,113
(iii) Sole power to dispose or to direct the disposition of
-0-
(iv) Shared power to dispose or to direct the disposition of
874,113
ITEM 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following: [ X ]
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
This statement is filed jointly by BB Biotech and Biotech Target. Biotech
Target is a wholly-owned subsidiary of BB Biotech.
Page 4 of 6 pages
5
CUSIP No. 015351109
-------------------------------------------------------------------------------
SIGNATURES
After reasonable inquiry and the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: February 14, 2001 By: /s/ Dubravka Racjnak
---------------------
Name: Dubravka Racjnak
---------------------
Title: Signatory Authority
---------------------
Date: February 14, 2001 By: /s/ Anders Hove
---------------------
Name: Anders Hove
---------------------
Title: Signatory Authority
---------------------
BIOTECH TARGET S.A.
Date: February 14, 2001 By: /s/ Dubravka Racjnak
---------------------
Name: Dubravka Racjnak
---------------------
Title: Signatory Authority
---------------------
Date: February 14, 2001 By: /s/ Anders Hove
---------------------
Name: Anders Hove
---------------------
Title: Signatory Authority
---------------------
Page 5 of 6 pages
6
CUSIP No. 015351109
-------------------------------------------------------------------------------
EXHIBIT INDEX
-------------
Exhibit 1: Agreement by and between BB Biotech and Biotech Target with respect
to the filing of this disclosure statement.*
---------------------
* Previously filed.
Page 6 of 6 pages